Skip to main content
OpenTrials
Completed

NCT Number: NCT02795559

Acute Effects of Dietary Fiber on Postprandial Responses in Lean and Overweight Subjects

It has been suggested that obesity occurs because the colonic microbes in obese individuals, compared to those who are lean, produce more short chain fatty acids during the fermentation of dietary fiber; this means that obese individuals obtain more energy from dietary fiber than lean. On the other hand, it is possible that the ability of colonic short chain fatty acids to improve glycemic control and suppress appetite may be reduced in obese subjects. The aim of this study was to determine the acute effects of 2 fibers commonly used as food ingredients, inulin and resistant starch, on postprandial serum responses of short chain fatty acids, glucose, insulin, free-fatty acids and selected gut hormones in lean and overweight or obese subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Glycemic Index Laboratories

Toronto, Ontario, M5C 2X3, Canada

About this study

The human colon (large intestine) contains hundreds of species of bacteria which exist in a symbiotic (mutually beneficial) relationship with their human host. The number and type of colonic bacteria varies in different people. Recent studies show that overweight individuals have different types of bacteria in their colons than lean subjects, and that as overweight subjects lose weight their colonic bacteria change to resemble those in lean subjects. It was suggested that this was because the bacteria in overweight people more efficiently ferment dietary fiber thus producing more SCFAs and providing more energy to the body. However, this is not consistent with other studies showing that high fiber intakes are associated with reduced risk of obesity.

Some studies have shown that overweight people have higher concentrations of SCFA in their stool samples. But the reasons for the difference in stool concentrations of SCFA have not been studied. Stool concentrations of SCFA may differ in lean and overweight people because of differences in type of bacteria in their colons, differences in dietary intakes or maybe because lean and overweight people absorb SCFA produced by bacteria differently.

Therefore, the objectives of this study were to:

  • determine the relationship between SCFA production and the acute effects of consuming an unabsorbed carbohydrate on blood SCFA, FFA, glucose, insulin, c-peptide and gut hormone responses in lean and overweight subjects
  • determine the types of bacteria in the stools of lean and overweight subjects
  • to see if the types of bacteria are correlated with body weight, the composition of the diet, breath gases, fecal SCFA and other demographic and lifestyle factors.

Healthy subjects with a BMI <25 (lean) or between 25 and 35 (overweight or obese; OWO) took part in a 2 phase study. In phase 1 subjects recorded their dietary intake for 3 days and then provided a stool sample for analysis of micro-organisms and short chain fatty acids. In phase 2 overnight fasted subjects were studied on 3 occasions separated by about a week. On each occasion subjects consumed a control test meal of dextrose, or dextrose plus inulin or dextrose plus resistant start and had breath and blood samples taken at intervals over 4 hours. Subjects were then given a standardized lunch and had more blood and breath samples taken over the next 2 hours.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • over 18 years of age

Exclusion criteria

  • Pregnant
  • BMI<18 or >39.9
  • diabetes
  • anaemia
  • use of diuretics of beta-blockers
  • regular user of antibiotics (≥1 course per year over the last 5 years)
  • any use of antibiotics within 3 months
  • use of laxatives, weight reducing agents, pre/probiotics or supplements known to influence gastrointestinal function within 3 months
  • presence of inflammatory bowel disease, malabsorption, motility disorder, gastrointestinal infection, short bowel, or other condition affecting gastrointestinal function
  • liver or kidney disease or major medical or surgical event (within the last 6 months) requiring hospitalization
  • high fibre intake (>30g/day) or other abnormal dietary pattern
  • on a weight-loss diet or not on their habitual diet in the two months prior to the study
  • unwilling or unable to give informed consent and/or comply with study protocol

Treatment and study plan

Glucose

Other

75g glucose dissolved in 300ml water

Inulin

Other

75g glucose plus 24g inulin dissolved in 300ml water

Resistant starch

Other

75g glucose plus 28g resistant starch in 300ml water

Primary outcomes

  1. Serum acetate response

    Time frame: 0 to 6 hours after the intervention

    Incremental area under the curve of the serum acetate response from the lowest concentration achieved during the first 3 hours to the end of the study (6hr)

Secondary outcomes

  1. Serum propionate response

    Time frame: 0 to 6 hours after the intervention

    Incremental area under the curve of the serum propionate response from the lowest concentration achieved during the first 3 hours to the end of the study (6hr)

  2. Serum butyrate response

    Time frame: 0 to 6 hours after the intervention

    Incremental area under the curve of the serum butyrate response from the lowest concentration achieved during the first 3 hours to the end of the study (6hr)

  3. Breath hydrogen response

    Time frame: 0 to 6 hours after the intervention

    Incremental area under the curve of the breath hydrogen response from the lowest concentration achieved during the first 3 hours to the end of the study (6hr)

  4. Energy intake

    Time frame: 3 days

    From 3-day diet record, mean energy intake.

  5. Fat intake

    Time frame: 3 days

    From 3-day diet record, mean total fat intake.

  6. Protein intake

    Time frame: 3 days

    From 3-day diet record, mean protein intake.

  7. Carbohydrate intake

    Time frame: 3 days

    From 3-day diet record, mean available carbohydrate intake.

  8. Dietary fiber intake

    Time frame: 3 days

    From 3-day diet record, mean dietary fiber intake.

  9. Fecal microbiota

    Time frame: 1 day

    Ion Torrent V6 16S-rRNA sequencing for comparison of phyla

  10. 0-2 hour Glucose response

    Time frame: 0 to 2 hours after consuming treatment

    Incremental area under the curve of the serum glucose response from fasting to 2 hours.

  11. 2-4 hour Glucose response

    Time frame: 2 to 4 hours after consuming treatment

    Incremental area under the curve of the serum glucose response from 2 to 4 hours.

  12. Second-meal glucose response

    Time frame: 0 to 2 hours after lunch

    Total area under the curve of the serum glucose response for 2 hours after lunch.

  13. 0-2 hour Insulin response

    Time frame: 0 to 2 hours after consuming treatment

    Incremental area under the curve of the serum insulin response from fasting to 2 hours

  14. 2-4 hour Insulin response

    Time frame: 2-4 hours after consuming treatment

    Incremental area under the curve of the serum insulin response from 2 to 4 hours.

  15. Second-meal Insulin response

    Time frame: 0-to 2 hours after lunch

    Total area under the curve of the serum insulin response for 2 hours after lunch.

  16. 0-2 hour c-peptide response

    Time frame: 0 to 2 hours after consuming treatment

    Incremental area under the curve of the serum c-peptide response from fasting to 2 hours.

  17. 2-4 hour c-peptide response

    Time frame: 2 to 4 hours after consuming treatment

    Incremental area under the curve of the serum c-peptide response from 2 to 4 hours.

  18. Second-meal c-peptide response

    Time frame: 0-2 hours after lunch

    Total area under the curve of the serum c-peptide response for 2 hours after lunch.

  19. Free-fatty acid rebound

    Time frame: 0 to 4 hours after consuming intervention

    Increase in serum free-fatty acid concentration from the lowest to the subsequent highest concentration before consuming lunch

  20. Acute total glucagon-like peptide-1 response

    Time frame: 0 to 4 hours after consuming intervention

    Incremental area under the curve of the serum total glucagon-like peptide-1 response from 0 to 4 hours.

  21. Post-lunch total glucagon-like peptide-1 response

    Time frame: 0 to 2 hours after consuming lunch

    Incremental area under the curve of the serum total glucagon-like peptide-1 response from 0 to 2 hours after lunch.

  22. Acute active glucagon-like peptide-1 response

    Time frame: 0 to 4 hours after consuming intervention

    Incremental area under the curve of the serum active glucagon-like peptide-1 response from 0 to 4 hours.

  23. Post-lunch active glucagon-like peptide-1 response

    Time frame: 0 to 2 hours after consuming lunch

    Incremental area under the curve of the serum active glucagon-like peptide-1 response from 0 to 2 hours after lunch.

  24. Acute peptide tyrosine tyrosine response

    Time frame: 0 to 4 hours after consuming intervention

    Incremental area under the curve of the serum PYY response from 0 to 4 hours.

  25. Post-lunch peptide tyrosine tyrosine response

    Time frame: 0 to 2 hours after consuming lunch

    Incremental area under the curve of the serum PYY response from 0 to 2 hours after lunch.

  26. Acute ghrelin response

    Time frame: 0 to 4 hours after consuming intervention

    Incremental area under the curve of the serum ghrelin response from 0 to 4 hours.

  27. Post-lunch ghrelin response

    Time frame: 0 to 2 hours after consuming lunch

    Incremental area under the curve of the serum ghrelin response from 0 to 2 hours after lunch.

Sponsors and collaborators

Lead sponsor

University of Toronto

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)

Registry information

Official study title

Role of Colonic Short Chain Fatty Acids in Obesity: Acute Effects of Inulin and Resistant Starch on Postprandial Short Chain Fatty Acid, Glucose, Insulin, Free-fatty Acid and Gut Hormone Responses

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Jun 10, 2016
Registry last updated
Jun 13, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.